Latest Breaking News On - Janet freeman daily - Page 1 : comparemela.com

U S Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)

The approval is based on the pivotal TRIDENT-1 trial, in which Augtyro successfully achieved a high objective response rate and durable response1 Augtyro adds to Bristol Myers Squibb’s growing.

United statesJanet freemanSamit hirawatJessicaj linBristol myers squibbDrug administrationAmerican cancer societyProfessor of medicine at harvard medical schoolLung cancer foundation of americaNational cancer instituteBristol myers squibb companyExchange commissionGlobal drug developmentConfidence intervalThoracic cancersMassachusetts general hospital

Bristol-Myers Squibb (BMY) Announces FDA Approval of Augtyro

Bristol-Myers Squibb (BMY) Announces FDA Approval of Augtyro
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesBristol myers squibbSamit hirawatJessicaj linJanet freemanProfessor of medicine at harvard medical schoolDrug administrationGlobal drug developmentConfidence intervalThoracic cancersMassachusetts general hospitalAssistant professorHarvard medical schoolImportant safety informationJanet freeman dailyMyers squibb

FDA Approves Augtyro for Patients With NSCLC Subset

The Food and Drug Administration approved Augtyro for patients with ROS1-positive metastatic non-small cell lung cancer based on a phase 1/2 trial.

United statesJessicaj linSamit hirawatJanet freemanBristol myers squibbDrug administrationHarvard medical schoolNew drug applicationThoracic cancersMassachusetts general hospitalHarvard medicalJanet freeman dailyLung cancer

Over Half of Targetable NSCLC Patients Miss Out on Correct Tx

Most patients with advanced non–small cell lung cancer (NSCLC) have tumors with actionable mutations, but two thirds of them are not receiving targeted therapy owing to gaps in clinical practice.

United statesSan diegoLa jollaSandipp patelJanet freemanJulier brahmerDaryl pritchardUniversity of californiaDrug administrationPersonalized medicine coalitionJanet freeman dailyClinical practiceMedscape medicalSidney kimmel comprehensive cancer centerJohns hopkinsPersonalized medicine